Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Targeting AP1S1 modulates the unfolded protein response and cell cycle and sensitizes triple-negative breast cancer to erlotinib.

Created on 15 Nov 2026

Authors

Rong Gong, Shilu Peng, Yiran Yang, Danyang Mei, Shilong Jiang, Hongyu Gao, Yan Cheng

Published in

Tissue & cell. Volume 105. Pages 104128. Nov 13, 2026. Epub Nov 13, 2026.

Abstract

Triple-negative breast cancer (TNBC) is an aggressive malignancy lacking actionable therapeutic targets. Intrinsic resistance to tyrosine kinase inhibitor (TKI) therapy remains a major barrier to improving clinical outcomes. Here, we identify adaptor-related protein complex 1 subunit sigma 1 (AP1S1) as an oncogenic regulator and a potential therapeutic vulnerability in TNBC. Through integrated multi-omics profiling and experimental validation, we found that AP1S1 is significantly overexpressed in breast cancer and correlates with advanced clinicopathological features and poor prognosis. Functionally, knockdown of AP1S1 inhibited cell proliferation, induced apoptosis, and triggered cell cycle arrest in vitro and in patient-derived organoids (PDOs). Single-cell RNA sequencing quantitatively confirmed that AP1S1 expression is specifically enriched in malignant cell populations and closely associates with hyperproliferation and stress-response pathways. Molecularly, AP1S1 is involved in a functional network involving both cell cycle progression and the unfolded protein response (UPR), and its high expression correlates with an "immune-desert" microenvironment characterized by depleted effector T cell infiltration. Furthermore, integrating pharmacogenomic analysis with in vitro and PDOs assays, we found that AP1S1 depletion increases the sensitivity of TNBC cells to erlotinib. Collectively, these findings identify AP1S1 as a multifaceted regulator of TNBC aggressiveness and therapy responsiveness, highlighting its potential as a therapeutic target to enhance TKI sensitivity and its association with immune exclusion.

PMID:
43033554
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement